About the Company

BioTime (NYSE: BTX) is a biotechnology company focused on regenerative medicine. The Company is developing therapies that utilize stem cells, biomaterials, lab-generated cells and tissues, and biologics. BioTime’s lead asset is Renevia, an adipose tissue replacement device being developed for use in various aesthetic dermatological applications. Renevia is in a pivotal trial for the treatment of HIV related facial lipoatrophy, with promising early data. BioTime is also pursuing the development of OpRegen, a proprietary injection of human embryonic stem cell (hESC) derived retinal pigment epithelium (RPE) cells for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company is conducting a Phase I/II dose-escalation study with OpRegen and data from the third and highest dose cohort are expected in 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research